Barclays Raises Encompass Health (NYSE:EHC) Price Target to $101.00

Encompass Health (NYSE:EHC) had its price objective upped by equities research analysts at Barclays from $95.00 to $101.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential upside of 30.00% from the company’s current price.

A number of other equities analysts have also recently issued reports on EHC. Truist Financial upped their price objective on shares of Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Friday, February 9th. William Blair restated an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Royal Bank of Canada restated an “outperform” rating and issued a $83.00 price target on shares of Encompass Health in a research report on Friday, February 9th. Mizuho increased their price target on Encompass Health from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, February 9th. Finally, Stephens reissued an “overweight” rating and issued a $85.00 price objective on shares of Encompass Health in a research note on Tuesday, January 16th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $83.22.

Encompass Health Price Performance

Shares of NYSE:EHC opened at $77.69 on Thursday. The firm has a 50 day moving average of $74.10 and a 200-day moving average of $68.80. The stock has a market capitalization of $7.78 billion, a PE ratio of 22.39, a PEG ratio of 1.42 and a beta of 0.93. The company has a current ratio of 1.28, a quick ratio of 1.28 and a debt-to-equity ratio of 1.19. Encompass Health has a 12 month low of $52.32 and a 12 month high of $78.11.

Encompass Health (NYSE:EHC) last issued its earnings results on Wednesday, February 7th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.83 by $0.12. The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Encompass Health had a net margin of 7.33% and a return on equity of 17.69%. On average, equities research analysts predict that Encompass Health will post 3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Encompass Health

Institutional investors have recently made changes to their positions in the stock. Principal Securities Inc. acquired a new position in shares of Encompass Health during the fourth quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. increased its stake in Encompass Health by 360.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after buying an additional 317 shares during the last quarter. McGlone Suttner Wealth Management Inc. purchased a new stake in Encompass Health in the 4th quarter valued at about $30,000. GAMMA Investing LLC purchased a new stake in Encompass Health in the 4th quarter valued at about $33,000. Finally, C M Bidwell & Associates Ltd. bought a new position in shares of Encompass Health during the 3rd quarter valued at approximately $35,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.